Endocrine Abstracts

A multidisciplinary team is responsible for the management of over 1,200 NET patients per year in our hospital. Tumor board decisions for peptide receptor radiotherapy (PRRT) are based on the Bad Berka Score which takes into account molecular imaging features and clinical aspects. The therapy plan for each patient is individualized. Retrospective analysis was performed in 1048 patients (age 4–85 years) with progressive NETs treated at our center since 2004 using Lu-177 (<...

Objectives: Copper-64 (64Cu, T1/2=12.7 h; Eβ+ max =0.65 MeV (17.9%); Eβ− max =0.57 MeV (39%)) is suitable for in-vivo PET imaging. Prostate specific membrane antigen (PSMA) is significantly over-expressed in undifferentiated prostate cancer tissue. We report the initial molecular imaging results with 64Cu-PSMA PET/CT in patients with prostate cancer.Methods: 64Cu labeled PSMA (mean administered ra...

Aim: To analyze the safety, efficacy and dosimetry of Lu-177 labeled prostate specific membrane antigen (PSMA) ligand 617 in patients with progressive metastatic castration-resistant prostate cancer (mCRPC), in comparison with Lu-177 PSMA I&T.Methods: Lu-177 PSMA-617 radioligand therapy (PRLT) was performed in 64 mCRPC patients. The median administered activity per treatment was 6 GBq. Ga-68 PSMA PET/CT was used for patient selection and follow-up. H...

Background: Peptide receptor radionuclide therapy (PRRT) is based on tumor somatostatin receptor (SSR) overexpression to deliver targeted isotope therapy. Functional imaging of SSR expression (SRE) is used as a predictor of efficacy, but there is no method to objectively predict PRRT efficacy. We report the efficacy of Predictive Quotient Index (PQI) to predict the utility of PPRT. PQI is derived from circulating NET transcript analysis (NETest) integrated with the tu...

Background: Paragangliomas are predominantly benign tumors, but in some cases invasive growth and also metastasis is observed. Given the limited number of nonsurgical treatment options, novel target structures for diagnostics and therapy of this tumor entity are urgently needed.Aims: In the present study the expression of the five somatostatin receptor (SSTR) subtypes as well as of the chemokine receptor CXCR4 and of the endothelin receptor A (ETA) was e...

Background: The efficacy of PRRT is based upon NET over expression of somatostatin receptor (SSR) to deliver targeted isotope therapy. SSR expression (Krenning scale) compared to Predictive Quotient Index (PQI) (circulating NET transcript analysis mathematically integrated with grade) indicates the latter is more accurate for predicting PRRT efficacy. We evaluated whether PQI was specifically predictive or was prognostic for PRRT compared to other therapeutic strategi...